NEW YORK, Sept. 30, 2015 /PRNewswire/ -- Verastem, Inc. (NASDAQ: VSTM) shares closed at $1.75 yesterday, down slightly after a day where the stock lost 67% of it value.
Investors of Verastem, Inc. may want to gain valuable insight by reading or due diligence. Get our report at the link below at no cost.
Copy and paste to browser may be required.
About Verastem, Inc.
Verastem, Inc. is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK and PI3K/mTOR.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This release and report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this release have not been compensated in any form by any source. A full disclaimer can be found by viewing due diligence. We are only human and may make mistakes. If you notice any errors or omissions, please notify us below.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.